Benzopyrone, a privileged scaffold in drug discovery: An overview of FDA‐approved drugs and clinical candidates

• Published in: Medicinal research reviews Vol. 44; no. 5; pp. 2035 - 2077
• Main Authors: Sharma, Venu, Sharma, Ankita, Wadje, Bhagyashri N., Bharate, Sandip B.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01-09-2024
• Subjects: anticoagulant; Anticoagulants; Asthma; benzopyrones; chromones; Clinical trials; coumarins; Drug development; FDA; Pharmaceutical sciences; Pharmacokinetics; psoralen; Psoriasis; R&D; Research & development; FDA; psoralen; coumarins; clinical trials; anticoagulant; chromones; benzopyrones
• ISSN: 0198-6325; 1098-1128; 1098-1128
• DOI: 10.1002/med.22032

Natural products have always served as an important source of drugs for treating various diseases. Among various privileged natural product scaffolds, the benzopyrone class of compounds has a substantial presence among biologically active compounds. One of the pioneering anticoagulant drugs, warfarin approved in 1954 bears a benzo‐α‐pyrone (coumarin) nucleus. The widely investigated psoriasis drugs, methoxsalen, and trioxsalen, also contain a benzo‐α‐pyrone nucleus. Benzo‐γ‐pyrone (chromone) containing drugs, cromoglic acid, and pranlukast were approved as treatments for asthma in 1982 and 2007, respectively. Numerous other small molecules with a benzopyrone core are under clinical investigation. The present review discusses the discovery, absorption, distribution, metabolism, excretion properties, and synthetic approaches for the Food and Drug Administration‐approved and clinical‐stage benzopyrone class of compounds. The role of the pyrone core in biological activity has also been discussed. The present review unravels the potential of benzopyrone core in medicinal chemistry and drug development.